GenomeArc Inc. is a biotech company on clinical genetics and drug discovery, and we enforce the development of fast algorithms to interpret genomic data through our flagship Horizon platform. We are proud to announce our early access program for Horizon, having scalability and accuracy in different populations across the globe.

Genome interpretation is highly complicated and requires the integration of multiple databases that are curated with precision. To solve these problems, the Horizon platform uses numerous proprietary databases and uses intelligent NLP (natural language processing) algorithms for its phenotype analysis. The interpretation also allows a fully automated genome analytics solution that helps genetic diagnosis following American College of Medical Genetics (ACMG) guidelines. The Horizon platform also provides an open-ended solution by allowing custom design integration for genomic and phenotypic datasets.

Horizon implements NLP models to interpret unstructured texts for the integration of phenotype with the genome. The platform is scalable and very fast in analyzing the full genome with a higher level of sensitivity and specificity. Recently, Horizon has been tested with 20,000 clinical genetic test samples reaching extremely high sensitivity and specificity. The platform comprises numerous well-curated and human-verified large-scale databases including rare genetic disorders, cancer genetics, and pharmacogenomics. Our goal is to vitally accelerate excellence in future precision medicine endeavors using Horizon.